OncoMatch/Clinical Trials/NCT06949098
Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer
Is NCT06949098 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Chemotherapy for rectal cancer stage i.
Treatment: Chemotherapy — This study is a single-center, single-arm, prospective clinical trial designed to evaluate the efficacy of local excision followed by postoperative chemoradiotherapy in patients with early-stage low/ultra-low rectal cancer. The study plans to enroll 60 patients with T1-2N0M0 low/ultra-low rectal cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Colorectal Cancer
Disease stage
Required: Stage CLINICAL STAGE I
Clinical stage I (cT1-2N0M0)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06949098 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage CLINICAL STAGE I is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages